Treatment with an antibody directed against nogo-a delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis

Human Molecular Genetics

Volumn 23, Issue 16, 2014, Pages 4187-4200

  Bros Facer, Virginie ^a   Krull, David ^b   Taylor, Adam ^b   Dick, James R T ^a   Bates, Stewart A ^b   Cleveland, Matthew S ^b   Prinjha, Rabinder K ^b   Greensmith, Linda ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; COPPER ZINC SUPEROXIDE DISMUTASE; GSK 577548; NOGO A ANTIBODY; PROTEIN NOGO A; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; ANTIBODY; MYELIN PROTEIN; PROTEIN NOGO; RTN4 PROTEIN, HUMAN; RTN4 PROTEIN, MOUSE; SOD1 PROTEIN, HUMAN; SOD1 PROTEIN, MOUSE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FAST MUSCLE; FEMALE; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOTONEURON; MOUSE; MUSCLE DENERVATION; MUSCLE INNERVATION; MUSCLE STRENGTH; MUSCLE TWITCH; NERVE CELL DEGENERATION; NEUROMUSCULAR DISEASE; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR SYNAPSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOLEUS MUSCLE; DRUG EFFECT; MALE; MOTOR UNIT; MSOD1 MOUSE; MUSCLE CELL; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SLOW MUSCLE FIBER; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; MUSCLE FIBERS, SLOW-TWITCH; MYELIN PROTEINS; NOGO PROTEINS; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE-1;

EID: 84904059232     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu136     Document Type: Article

References (47)

1. Ticozzi, N., Tiloca, C., Morelli, C., Colombrita, C., Poletti, B., Doretti, A., Maderna, L., Messina, S., Ratti, A. and Silani, V. (2011) Genetics of familial Amyotrophic lateral sclerosis. Arch. Ital. Biol., 149, 65-82.
2. Renton, A.E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L. et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 7, 257-268.
3. Bruijn, L.I., Miller, T.M. and Cleveland, D.W. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci., 27, 723-749.
4. Bensimon, G., Lacomblez, L. and Meininger, V. (1994) Acontrolled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 330, 585-591.
5. Miller, R.G., Mitchell, J.D., Lyon, M. and Moore, D.H. (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 24, CD001447.
6. Contestabile, A. (2011) Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr. Med. Chem., 18, 5655-5665.
7. Boillée, S., Vande Velde, C. and Cleveland, D.W. (2006) ALS: a disease of motor neurons and their non-neuronal neighbours. Neuron, 52, 39-59.
8. Cleveland, D.W. and Rothstein, J.D. (2001) From Charcot to Lou Gehrig:deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci., 2, 806-819.
9. Haidet-Phillips, A.M., Hester, M.E., Miranda, C.J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M.J., Foust, K.D. et al. (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol., 29, 824-828.
10. Ilieva, H., Polymenidou, M. and Cleveland, D.W. (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol., 187, 761-772.
11. Fischer, L.R., Culver, D.G., Tennant, P., Davis, A.A., Wang, M., Castellano-Sanchez, A., Khan, J., Polak, M.A. and Glass, J.D. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol., 185, 232-240.
12. G93A mouse model of ALS. Amyotroph. Lateral Scler., 13, 378-392.
13. Caroni, P. and Schwab, M.E. (1988) Antibody against myelin-associated inhibitor of neurite outgrowth neutralizes nonpermissive substrate properties of CNS white matter. Neuron, 1, 85-96.
14. Chen, M.S., Huber, A.B., van der Haar, M.E., Frank, M., Schnell, L., Spillmann, A.A., Christ, F. and Schwab, M.E. (2000) Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature, 403, 434-439.
15. Prinjha, R., Moore, S.E., Vinson, M., Blake, S., Morrow, R., Christie, G., Michalovich, D., Simmons, D.L. and Walsh, F.S. (2000) Inhibitor of neurite outgrowth in humans. Nature, 403, 383-384.
16. GrandPres, T., Nakamura, F., Vartanian, T. and Strittmatter, S.M. (2000) Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature, 403, 439-444.
17. Bareyre, F.M., Haudenschild, B. and Schwab, M.E. (2002) Long lasting sprouting and gene expression changes induced by the monoclonal antibody IN-1 in the adult spinal cord. J. Neurosci., 22, 7097-7110.
18. Li, S. and Strittmatter, S.M. (2003) Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J. Neurosci., 23, 4219-4227.
19. Dupuis, L., Gonzalez De Aguila, J.L., Di Scala, F., Rene, F., De Tapia, M., Pradat, P.F., Lacomblez, L., Seihlan, D., Prinjha, R., Walsh, F.S., Meinger, V. and Loeffler, J.P. (2002) Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol. Dis., 10, 358-365.
20. Jokic, N., Gonzalez de Aguilar, J.L., Dimou, L., Lin, S., Fergani, A., Ruegg, M.A., Schwab, M.E., Dupuis, L. and Loeffler, J.P. (2006) The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep., 7, 1162-1167.
21. Su, Y., Wang, F., Teng, Y., Zhao, S.G., Cui, H. and Pan, S.H. (2009) Axonal regeneration of optic nerve after crush in Nogo66 receptor knockout mice. Neurosci. Lett., 460, 223-226.
22. Freund, P., Wannier, T., Schmidlin, E., Bloch, J., Mir, A., Schwab, M.E. and Rouiller, E. (2007) Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J. Comp. Neurol., 502, 644-659.
23. Tsai, S.Y., Papadopoulos, C.M., Schwab, M.E. and Kartje, G.L. (2007) Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats. Stroke, 42, 186-190.
24. Zörner, B. and Schwab, M.E. (2010) Anti-Nogo on the go: from animal models to a clinical trial. Ann. N. Y. Acad. Sci., 1198 (Suppl. 1), E22-E34.
25. Sharp, P.S., Dick, J.R. and Greensmith, L. (2005) The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience, 130, 897-910.
26. Kieran, D., Kalmar, B., Dick, J.R., Riddoch-Contreras, J., Burnstock, G. and Greensmith, L. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med., 10, 402-405.
27. Kalmar, B., Novoselov, S., Gray, A., Cheetham, M.E., Margulis, B. and Greensmith, L.J. (2008) Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. Neurochemistry, 107, 339-350.
28. Saxena, S., Cabuy, E. and Caroni, P. (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat. Neurosci., 12, 627-636.
29. Jokic, N., Gonzalez de Aguilar, J.L., Pradat, P.F., Dupuis, L., Echaniz-Laguna, A., Muller, A., Dubourg, O., Seilhean, D., Hauw, J.J., Loeffler, J.P. and Meininger, V. (2005)Nogoexpression in muscle correlates with amyotrophic lateral sclerosis severity. Ann. Neurol., 57, 553-556.
30. Frey, D., Schneider, C., Xu, L., Borg, J., Spooren, W. and Caroni, P. (2000) Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci., 20, 2534-2542.
31. Kieran, D. and Greensmith, L. (2004) Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience, 125, 427-439.
32. Joo, I.S., Hwang, D.H., Seok, J.I., Shin, S.K. and Kim, S.U. (2007) Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Clin. Neurol., 3, 181-186.
33. Waibel, S., Reuter, A., Malessa, S., Blaugrund, E. and Ludolph, A.C. (2004) Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol., 251, 1080-1084.
34. G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis. Model Mech., 4, 686-700.
35. Igaz, L.M., Kwong, L.K., Lee, E.B., Chen-Plotkin, A., Swanson, E., Unger, T., Malunda, J., Xu, Y., Winton, M.J., Trojanowski, J.Q. and Lee, V.M. (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest., 121, 726-738.
36. Johnson, J.O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V.M., Trojanowski, J.Q., Gibbs, J.R., Brunetti, M., Gronka, S., Wuu, J. et al. (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron, 68, 857-864.
37. Kwiatkowski, T.J. Jr, Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T. et al. (2009) Science, 323, 1205-1208.
38. Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H. et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Science, 465, 223-226.
39. Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J.C., Williams, K.L., Buratti, E. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319, 1668-1672.
40. Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323, 1208-1211.
41. Dejesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J. et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72, 245-256.
42. Joyce, P.I., Fratta, P., Fisher, E.M. and Acevedo-Arozena, A. (2011) SOD1 andTDP-43animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome, 22, 420.
43. Pradat, P.F., Bruneteau, G., Gonzalez de Aguilar, J.L., Dupuis, L., Jokic, N., Salachas, F., Le Forestier, N., Echaniz-Laguna, A., Dubourg, O., Hauw, J.J. et al. (2007) Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann. Neurol., 62, 15-20.
44. Li, S., Liu, B.P., Budel, S., Li, M., Ji, B., Walus, L., Li, W., Jirik, A., Rabacchi, S., Choi, E. et al. (2004) Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J. Neurosci., 24, 10511-10520.
45. Liebscher, T., Schnell, L., Schnell, D., Scholl, J., Schneider, R., Gullo, M., Fouad, K., Mir, A., Rausch, M., Kindler, D., Hamers, F.P. and Schwab, M.E. (2005) Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann. Neurol., 58, 706-719.
46. Gurney, M.E. (1994) Transgenic-mouse model of amyotrophic lateral sclerosis. N. Engl. J. Med., 331, 1721-1722.
47. Namba, T., Nakamura, T. and Grob, D. (1967) Staining for nerve fiber and cholinesterase activity in fresh frozen sections. Am. J. Clin. Pathol., 47, 74-77.